N
Naganori Nao
Researcher at National Institutes of Health
Publications - 22
Citations - 2280
Naganori Nao is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Coronavirus & Human metapneumovirus. The author has an hindex of 14, co-authored 22 publications receiving 1434 citations.
Papers
More filters
Journal ArticleDOI
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
Shutoku Matsuyama,Naganori Nao,Kazuya Shirato,Miyuki Kawase,Shinji Saito,Ikuyo Takayama,Noriyo Nagata,Tsuyoshi Sekizuka,Hiroshi Katoh,Fumihiro Kato,Masafumi Sakata,Maino Tahara,Satoshi Kutsuna,Norio Ohmagari,Makoto Kuroda,Tadaki Suzuki,Tsutomu Kageyama,Makoto Takeda +17 more
TL;DR: It is shown that a TMPRSS2-expressing VeroE6 cell line is highly susceptible to Sars-CoV-2 infection, making it useful for isolating and propagating SARS-Cov-2.
Journal ArticleDOI
Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan.
Kazuya Shirato,Naganori Nao,Harutaka Katano,Ikuyo Takayama,Shinji Saito,Fumihiro Kato,Hiroshi Katoh,Masafumi Sakata,Yuichiro Nakatsu,Yoshio Mori,Tsutomu Kageyama,Shutoku Matsuyama,Makoto Takeda +12 more
TL;DR: In this article, two nested RT-PCR and two real-time RTPCR assays were adapted for use in Japan to detect 25 positive cases of infection in Japan.
Posted ContentDOI
The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15
Shutoku Matsuyama,Miyuki Kawase,Naganori Nao,Kazuya Shirato,Makoto Ujike,Wataru Kamitani,Masayuki Shimojima,Shuetsu Fukushi +7 more
TL;DR: Observations suggest that the effect of ciclesonide was specific to coronavirus, suggesting this is a candidate drug for treatment of patients suffering MERS or COVID-19.
Journal ArticleDOI
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells.
Shutoku Matsuyama,Miyuki Kawase,Naganori Nao,Kazuya Shirato,Makoto Ujike,Wataru Kamitani,Masayuki Shimojima,Shuetsu Fukushi +7 more
TL;DR: Observations indicate that the suppressive effect of ciclesonide on viral replication is specific to coronaviruses, highlighting it as a candidate drug for the treatment of COVID-19 patients.
Journal ArticleDOI
Environmental Sampling for Severe Acute Respiratory Syndrome Coronavirus 2 During a COVID-19 Outbreak on the Diamond Princess Cruise Ship.
Takuya Yamagishi,Makoto Ohnishi,Matsunaga N,Kensaku Kakimoto,Hajime Kamiya,Kiyoko Okamoto,Motoi Suzuki,Yoshiaki Gu,Mikiyo Sakaguchi,Taichi Tajima,Saho Takaya,Norio Ohmagari,Makoto Takeda,Shutoku Matsuyama,Kazuya Shirato,Naganori Nao,Hideki Hasegawa,Tsutomu Kageyama,Ikuyo Takayama,Shinji Saito,Koji Wada,Retsu Fujita,Hiroki Saito,Keiji Okinaka,Mathew Griffith,Amy Parry,Brenda Barnetson,James Leonard,Takaji Wakita +28 more
TL;DR: During a COVID-19 outbreak on the Diamond Princess cruise ship, environmental surfaces after passengers and crew vacated cabins were sampled to investigate transmission risk of SARS-CoV-2 from symptomatic and asymptomatic patients.